SUPN as reported
Supernus Pharmaceuticals, Inc. reported $777M of revenue over the trailing twelve months, +16% on the year before. 11 reported series are charted on this page, each one as filed.
$777M
Revenue, trailing twelve months · to Q1 2026 · +16% against the twelve months before
- Net Income
- −$29M
Net Income · −147% year on year · trailing twelve months to Q1 2026
- Free Cash Flow
- $82M
Free Cash Flow · −50% year on year · trailing twelve months to Q1 2026
- Op Margin
- −7.5%
Op Margin · trailing twelve months to Q1 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $777M | +16% | Q1 2026 |
| Net Income | −$29M | −147% | Q1 2026 |
| EPS | −$0.51 | −146% | Q1 2026 |
| Gross Margin | 89% | n/a | Q1 2026 |
| Op Margin | −7.5% | n/a | Q1 2026 |
| Net Margin | −3.2% | n/a | Q1 2026 |
| ROE | −0.52% | n/a | Q1 2026 |
| ROA | −0.32% | n/a | Q1 2026 |
| ROIC | 4.8% | n/a | Q1 2023 · 12 quarters behind |
| Free Cash Flow | $82M | −50% | Q1 2026 |
| P/E | 28.4 | n/a | Q2 2025 |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
Supernus Pharmaceuticals, Inc. (SUPN) - Revenue & ProfitRevenue & ProfitSupernus Pharmaceuticals, Inc. (SUPN)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com
Drug Manufacturers - Specialty & Generic
Ranks #19 of 28 by Smart Score